The Galien Forum USA 2020

PANEL
2

Co-Moderators
Joel S. Marcus
Co-Founder, Alexandria Summit;
Executive Chairman & Founder, Alexandria Real Estate Equities, Inc./Alexandria Venture Investments

Lynne Zydowsky, PhD
President & Co-Founder, Alexandria Summit;
Chief Science Officer, Alexandria Real Estate Equities, Inc./Alexandria Venture Investments

Panelists
Stéphane Bancel
Chief Executive Officer
Moderna, Inc.

Paul Stoffels, MD
Executive Vice President, Chief Scientific Officer
Johnson & Johnson

Panel Intro

COVID-19 Vaccine Development and the Enduring Impact on Life Sciences Innovation –  Speed, Collaboration, Clinical Trial Advancement and Manufacturing


Joel S. Marcus Co-Moderator
Joel S. Marcus
Co-Founder, Alexandria Summit;
Executive Chairman & Founder, Alexandria Real Estate Equities, Inc./Alexandria Venture Investments

Joel Marcus is the Executive Chairman & Founder of Alexandria Real Estate Equities, Inc. (NYSE:ARE), the urban office REIT that pioneered the life science real estate niche in 1994 and is longest-tenured owner, operator, and developer uniquely focused on collaborative life science, technology, and agtech campuses in AAA innovation cluster locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, and Seattle.

Prior to serving as the company’s full-time Executive Chairman, Mr. Marcus served as CEO from March 1997 to April 2018 and also as Chairman from May 2007 to April 2018. Since co-founding Alexandria as a garage startup with $19 million in Series A capital, he has led its growth into an S&P 500 company with a total market cap of over $27 billion. In 1996, he founded Alexandria Venture Investments, the company’s venture capital arm, to strategically invest in promising life science, technology, and agtech companies that will positively impact people’s lives.

In 2011, Mr. Marcus co-founded the Alexandria Summit® as a highly collaborative, neutral platform that convenes its preeminent global life science and healthcare networks to address the most critical challenges facing human health. He serves on the boards of Applied Therapeutics (NASDAQ:APLT), Frequency Therapeutics (NASDAQ:FREQ), Intra-Cellular Therapies (NASDAQ:ITCI), MeiraGTx (NASDAQ:MGTX), the Emily Krzyzewski Center, FNIH, the National Medal of Honor Museum, the Navy SEAL Foundation, the Parker Institute for Cancer Immunotherapy, and Robin Hood. Additionally, he serves as a trustee of the 9/11 Memorial & Museum.


Lynne Zydowsky, PhDCo-Moderator
Lynne Zydowsky, PhD
President & Co-Founder, Alexandria Summit;
Chief Science Officer, Alexandria Real Estate Equities, Inc./Alexandria Venture Investments

Lynne Zydowsky, PhD, President and Co-Founder of the Alexandria Summit and Chief Science Officer of Alexandria Real Estate Equities, Inc./Alexandria Venture Investments, and President of Zydowsky Consultants, is an experienced executive in the life science industry who has been involved in the launching and building of several successful companies. With over 20 years of experience, she has played key roles in corporate development, operations, and finance. She is a longstanding advocate for biomedical research and the advancement of global health.

In 2003, Dr. Zydowsky founded Zydowsky Consultants, a consulting practice offering services to life science companies. Prior to that, Dr. Zydowsky was Co-Founder and Chief Operating Officer of Renovis, Inc. (now Evotec) and served as Vice President of Pharmaceutical Business Development at Exelixis, Inc. As part of their executive management teams, she contributed to the growth and development of both companies, which led to their initial public offerings.

The Alexandria Summit, a neutral, interactive platform, co-founded in 2011 by Mr. Joel Marcus, Dr. Zydowsky, and Ms. Deeda Blair, convenes a diverse group of visionary stakeholders for transformative discussions and collaborations that help drive the discovery and development of novel, cost-effective therapies; shape policy to advance innovation that saves lives and cures disease; and inspires new ways of addressing the urgent need to transform our healthcare system.

Dr. Zydowsky currently serves on the Board of Directors for the Reagan-Udall Foundation for the FDA (since October 2018), Yumanity Therapeutics (since 2019), and Vindara, for which she is Board Chair (since 2019); the Board of Trustees for Butler University (since September 2016); and the Discovery Council for Harvard Medical School (since August 2018). She serves as a Board Observer for OneFifteen, a non-profit healthcare ecosystem dedicated to the full and sustained recovery of people living with opioid addiction, on behalf of Alexandria Real Estate Equities, Inc./Alexandria Venture Investments. Dr. Zydowsky is also a key member of Alexandria’s COVID-19 Task Force.

Dr. Zydowsky is also personally engaged in critical philanthropic efforts as a member of the West Coast Board for the international non-profit buildOn, an organization focused on breaking the cycle of poverty, illiteracy, and low expectations through its after-school programs for urban teens based on changing lives and communities through service locally and globally.

Dr. Zydowsky earned her PhD in Chemistry from The Ohio State University and was a National Institutes of Health postdoctoral fellow in the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. She has a Bachelor of Science degree in Pharmacy from Butler University.


Stephane BancelStéphane Bancel
Chief Executive Officer
Moderna, Inc.

Stéphane Bancel has served as Moderna’s Chief Executive Officer since October 2011 and as a member of Moderna’s board of directors since March 2011. Before joining the Company, Mr. Bancel served for five years as Chief Executive Officer of the French diagnostics company bioMérieux SA. From July 2000 to March 2006, he served in various roles at Eli Lilly and Company, including as Managing Director, Belgium and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Lilly, Mr. Bancelserved as Asia-Pacific Sales and Marketing Director for bioMérieux.

Mr. Bancel currently serves on the board of directors of Qiagen N.V. and Indigo. He is currently a Venture Partner at Flagship Pioneering and a trustee of the Museum of Science in Boston. Mr. Bancel holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an MBA from Harvard Business School.


Paul Stoffels_P2

Paul Stoffels, MD
Executive Vice President, Chief Scientific Officer
Johnson & Johnson
Paul Stoffels is a visionary leader who inspires and drives transformational innovation to bring years of life and quality of life to millions of people around the world.

As Chief Scientific Officer, he spearheads the innovation agenda for the Johnson & Johnson Family of Companies. He also is a pioneer in global public health and steers the company’s strategy to make innovative medicines and technologies accessible in the world’s most vulnerable communities and resource-poor settings.

Dr. Stoffels’ commitment to fueling innovation and finding the best science, wherever it exists, is the driving force behind the launch of Johnson & Johnson Innovation in 2013, which he now leads to foster science and technology through strategic partnerships, licensing and acquisitions.

Dr. Stoffels joined Johnson & Johnson in 2002 with the acquisition of Virco and Tibotec, where he led the development of leading HIV therapies. He began his career as a physician in Africa.